Mustargen® (mechlorethamine) – Product discontinuation

- On October 4, 2018, the FDA announced the discontinuation of Recordati Rare Diseases' Mustargen (mechlorethamine) 10 mg injection.
    - Recordati has decided to discontinue manufacture, distribution and sale of Mustargen due to extremely low demand.
    - Sales will be allowed through December 31, 2018.

- Mustargen, administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma.

- Mustargen, administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion.

- Mustargen carries a boxed warning that it is highly toxic and inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided; avoid exposure during pregnancy; extravasation of the drug into subcutaneous tissues results in a painful inflammation; and should be administered under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.